Premium
The safety and efficacy of subcutaneous birch pollen immunotherapy – a one‐year, randomised, double‐blind, placebo‐controlled study
Author(s) -
Bødtger U.,
Poulsen L. K.,
Jacobi H. H.,
Malling H.J.
Publication year - 2002
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1034/j.1398-9995.2002.1o3532.x
Subject(s) - unit (ring theory) , medicine , allergy , family medicine , university hospital , pediatrics , psychology , immunology , mathematics education
There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.